CASE SERIES: RTPA INFUSION AS SALVAGE THERAPY FOR PROLONGED CRITICALLY ILL COVID-19 PATIENTS

ABSTRACT

RTPA regimen was approximated in each patient to receive a bolus of 0.5-1 mg/kg and a subsequent infusion rate of 1-5 mg/kg/hr actively titrated by the ICU Attending physician, guided by serial fibrinogen levels. B Methods: b Following IRB approval, retrospective data was collected from 5 patients with severe, prolonged (>10 days hypoxemia) COVID-19, from April to May, 2020 that received bolus and infusion rTPA followed by apixaban and clopidogrel at conclusion of rTPA infusion. B Results: b 2 of the 5 patients encountered bleeding at central lines within 6 hours of rTPA bolus, to prompt the Intensivist to pause the rTPA infusion and apply PRBC support. [Extracted from the article] Copyright of Critical Care Medicine is the property of Lippincott Williams & Wilkins and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)